Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 456906 vs Semaglutide Receptor Occupancy in Obesity
NCT05202353Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of survodutide in obesity (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of glucagon (GCG) receptors occupancy in the liver at 17 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05202353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202353.